In8bio
Yahoo Finance • last year
IN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma
All patients treated with INB-200 who completed mandated doses to date have exceeded a progression-free survival (PFS) of seven months Most patients exceeded the expected median PFS based on age and tumor status; two patients from Cohort... Full story
Yahoo Finance • last year
IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting
Company will present “late-breaker” poster detailing updated clinical data from Phase 1 trial of INB-200 Company-sponsored Phase 2 trial of INB-400 to be showcased in Trials-in-Progress (TIPs) poster NEW YORK, Nov. 10, 2023 (GLOBE NEWS... Full story
Yahoo Finance • last year
IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Completed dose escalation in Phase 1 Trial of INB-100 with updated clinical data to be presented at the American Society of Hematology (ASH) Annual Meeting on December 11, 2023 (Abstract Number: 4853). Held Research & Development Day, feat... Full story
Yahoo Finance • last year
IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Data demonstrate the ability of single and repeat doses of INB-200, DeltEx drug-resistant immunotherapy (DRI) gamma-delta T cell therapy, to induce T cell persistence and a sustained immune response. A treated patient, with paired tissue b... Full story
Yahoo Finance • last year
IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
This data represents a step forward in developing next-generation ‘off-the-shelf’ iPSC derived gamma-delta T cells. Our proprietary expansion methods are serum and feeder-free and have the potential to produce billions of iVδ1 T cells.IN8b... Full story
Yahoo Finance • last year
IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting
New dataon thecompleted dose-escalation of this Phase 1 trial highlights promising efficacy of INB-100 in patientswith hematologic malignancies; updated data on durability of responses and long-term complete responses (CRs) to be presented... Full story
Yahoo Finance • last year
IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will particip... Full story
Yahoo Finance • last year
IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma
Enrollment is now open in the company-sponsored Phase 2 clinical trial of INB-400 in patients with newly diagnosed glioblastoma multiforme (GBM). Enrollment completed in the dose escalation phase of the investigator-sponsored trial of INB... Full story
Yahoo Finance • last year
IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting
NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced two poster presentations reporting positive... Full story
Yahoo Finance • last year
IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City
Management presentations will highlight IN8bio’s clinical and scientific programs, including upcoming data releases at several upcoming fall medical meetings Featured presentations by clinical thought leaders including Leo Luznik, M.D., Pr... Full story
Yahoo Finance • last year
IN8bio to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will partici... Full story
Yahoo Finance • last year
IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents
Newly granted patents expand the use of the DeltEx Drug Resistant Immunotherapy (DRI) platform to encompass Chimeric Antigen Receptor T-cell (CAR-T) and checkpoint inhibitors (CPIs). Broadens IN8bio’s foundational intellectual property (IP... Full story
Yahoo Finance • last year
IN8bio to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will partici... Full story
Yahoo Finance • last year
IN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference
NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will particip... Full story
Yahoo Finance • 2 years ago
IN8bio's DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer
Preclinical results showcase the potential for the strong synergistic combination of chemotherapy and gamma-delta T cell therapy to target solid tumors beyond the brain The DeltEx platform is the basis for IN8bio’s clinical stage gamma-de... Full story
Yahoo Finance • 2 years ago
IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
Presented positive INB-100 data showing long-term complete remissions (CR) and elevated gamma-delta T cell levels in 100% of evaluable treated leukemia patients; Dose Level 2 selected as the recommended Phase 2 dose (RP2D) for the ongoing... Full story
Yahoo Finance • 2 years ago
IN8bio Announces New Preclinical Data in Ovarian Cancer to be Presented at ASGCT 26th Annual Meeting
Preclinical data demonstrates that gamma-delta T cells have the ability to target other solid tumors such as ovarian cancer, supporting the development of these technologies outside of brain tumors The data suggest that INB-400, a clinical... Full story
Yahoo Finance • 2 years ago
IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors
Dr. Jeremy Graff spent 17 years at Eli Lilly and Company, where he built and led the translational oncology group, supporting and advancing 31 clinical assets in Eli Lilly’s oncology portfolio He is a highly respected industry leader in on... Full story
Yahoo Finance • 2 years ago
IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in Glioblastoma (GBM) to be Presented at 2023 ASCO Annual Meeting
NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced an oral presentation at the upcoming 2023 Am... Full story
Yahoo Finance • 2 years ago
IN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma
First-ever orphan drug designation for genetically modified gamma-delta T cell therapies This orphan drug designation offers potential 7-year market exclusivity for both autologous (INB-400) and allogeneic (INB-410) candidates INB-400 is... Full story
